A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2004
11/04/2004	WO2004094466A2 Recombinant influenza viruses holding a mutation in a transmembrane protein gene
11/04/2004	WO2004094462A2 Methods of peptide preparation
11/04/2004	WO2004093911A1 Pharmaceutical composition for prostatic disease treatment
11/04/2004	WO2004093909A1 Methods to regulate biofilm formation
11/04/2004	WO2004093906A1 Immunogenic composition and methods
11/04/2004	WO2004093905A1 Human cytomegalovirus antigens expressed in mva and methods of use
11/04/2004	WO2004093904A2 Modified live vaccines comprising bhv-1(ibr) and/or bvdv pregnant and nursing cattles
11/04/2004	WO2004093903A2 Methods and compositions for immunomodulation using cd1 antigens
11/04/2004	WO2004093901A1 Compositions and methods for treating poxvirus infection
11/04/2004	WO2004093831A2 Cytokine-expressing cellular vaccine combinations
11/04/2004	WO2004093825A2 Methods for obtaining colonization factors from bacterial strains
11/04/2004	WO2004083372A3 Modulators of the notch signaling pathway immobilized on particles for modifying immune responses
11/04/2004	WO2004062584A3 Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
11/04/2004	WO2004060319A3 Immunostimulatory combinations
11/04/2004	WO2004058142A3 Improved combine vaccine against mycoplasma hyopneumoniae and porcine viruses
11/04/2004	WO2004053095A3 In situ maturation of dendritic cells
11/04/2004	WO2004052925A3 Actinobacillus pleuropneumoniae virulence genes
11/04/2004	WO2004050883A3 Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis b core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine
11/04/2004	WO2004048575A3 Streptococcus pneumoniae surface polypeptides
11/04/2004	WO2004043340A3 Alpha 5 beta 1 and its ability to regulate the cell survival pathway
11/04/2004	WO2004035007A3 Transmucosal administration of aggregated antigens
11/04/2004	WO2004033705A3 Viral interferon antagonists and uses therefor
11/04/2004	WO2004011484A3 Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
11/04/2004	WO2004009618A3 Recombinant production of mixtures of antibodies
11/04/2004	WO2003090512A3 Regeneration of endogenous myocardial tissue by induction of neovascularization
11/04/2004	WO2003076473A8 Specific ab1'-antibodies against tumour-associated antigen ca 125
11/04/2004	WO2003063799A3 Compositions and methods for systemic inhibition of cartilage degradation
11/04/2004	WO2003042370A3 New gene expressed in prostate cancer and methods of use
11/04/2004	WO2003000183A3 Method of treating atherosclerosis and other inflammatory diseases
11/04/2004	WO2002072030A8 High affinity integrin polypeptides and uses thereof
11/04/2004	US20040220388 Novel heterodimeric fusion proteins
11/04/2004	US20040220142 Imine-forming polysaccharide adjuvants and immunostimulants
11/04/2004	US20040220111 administering polypeptide in mixturte with carrier; topical applying surface of body; wound healing agents; tissue repair
11/04/2004	US20040220098 Inhibin compositions and methods of enhancing fertility and growth
11/04/2004	US20040220097 Drug screening for compounds that modulate the function of anti-apoptotic protein Bcl-2 to induce apoptosis; identifying antitumor agents
11/04/2004	US20040220079 Inhibitors of Memapsin 2 and use thereof
11/04/2004	US20040220076 Prevention of recurrent viral disease
11/04/2004	US20040219642 Using expression vector comprising nucleotide sequences coding interferon-specific transcriptional regulators and interferon receptors to transform cells and intensify expression of interferon; antiviral agents; antitumor agents
11/04/2004	US20040219639 Immunogenic fusion polypeptide comprising lytic epitopes for use in developing vaccine for prevention of mastitis in dairy cattle; veterinary medicine; immunotherapy
11/04/2004	US20040219637 Soluble recombinant botulinum toxins having a C-terminal portion of a heavy chain, a N-terminal portion of a heavy chain and a light chain
11/04/2004	US20040219633 Method of producing recombinant antibodies
11/04/2004	US20040219597 Using cytokeratin marker peptides as diagnostic, prognostic and treatment tools for inflammations and/or infections in animals or humans; sepsis prevention; veterinary medicine
11/04/2004	US20040219591 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
11/04/2004	US20040219587 Vaccine against lipopolysaccharide core
11/04/2004	US20040219585 Comprises nucleotide sequences coding bacterial outer membrane protein for use in diagnosis, treatment and prevention of infection; antisense bactericidal agent; microbiocides; immunoassy
11/04/2004	US20040219563 Determining timing of transcriptional activation or repression of genes associated cell differentiation; identifying temporal and spatial gene expression patterns that control differentiation of stem cells; tissue engineering and therapeutic transplantation
11/04/2004	US20040219224 Spherical protein particles and methods for making and using them
11/04/2004	US20040219203 Anti-CD74 immunoconjugates and methods
11/04/2004	US20040219171 In ovo protection against infectious bronchitis
11/04/2004	US20040219170 Viruses encoding mutant membrane protein
11/04/2004	US20040219168 Preparing preferential cells from blood mononucler cells in culture; obtain monocytes, incubate with interferon; use as biodrugs treating viral infections, lymphoma, neoplastic disease induced by Epstein-Barr virus, therapeutic vaccination
11/04/2004	US20040219166 EIA vaccine and diagnostic
11/04/2004	US20040219165 Streptococcus pneumoniae antigens
11/04/2004	US20040219164 Advanced antigen presentation platform
11/04/2004	US20040219163 Cell of vector that encodes the antigen
11/04/2004	US20040219162 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
11/04/2004	US20040219161 Include recombinant expression constructs containing nucleic acids encoding target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves
11/04/2004	US20040219159 Immunogenic composition of mycobacteria from modified protein; heat shock proteins
11/04/2004	US20040219158 Cystic fibrosis
11/04/2004	US20040219157 Composition comprising a prebiotic for decreasing inflammatory process and abnormal actibation of non-specific immune parameters
11/04/2004	US20040219155 antibody, immunoconjugate and duramycin-based compositions; bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases
11/04/2004	US20040219153 Synergistic tumorcidal response induced by histamine
11/04/2004	US20040219152 Methods for modulating angiogenesis with apelin compositions
11/04/2004	US20040219151 Tetraspan protein and uses thereof
11/04/2004	US20040219148 comprising an agent that targets an interleukin-15 receptor and a second agent that inhibits a costimulatory signal transmitted between a T cell and an antigen-presenting cell; treating autoimmune diseases, AIDS, vascular injuries or organ, tissue or cell transplant recipients
11/04/2004	US20040219147 administering an anti-inflammatory compound, especially an antibody to a complement component or an NSAID, to a subject receiving a stent in connection with percutaneous transluminal coronary angioplasty.
11/04/2004	US20040219146 Prevention and treatment of amyloidogenic disease
11/04/2004	US20040219145 Compositions and methods to modulate immune and inflammatory responses
11/04/2004	US20040219144 administering an anti-human NGF monoclonal antibody capable of binding hNGF with an affinity in the nanomolar range, and inhibiting the binding of hNGF to human TrkA (hTrkA) in vivo, wherein said antibody has no significant adverse effect on the immune system
11/04/2004	US20040219142 Treatment of skin and nail disorders using TNFalpha inhibitors
11/04/2004	US20040219096 Enhancing interferon gamma production using interleukin 27; treating immune and proliferative disorders
11/04/2004	CA2823468A1 Compositions and methods for the therapy of inflammatory bowel disease
11/04/2004	CA2528503A1 Tolerance to graft prior to thymic regeneration
11/04/2004	CA2526914A1 Compositions and methods relating to stop-1
11/04/2004	CA2526887A1 Splice variants of human voltage-gated calcium channel alpha2delta-2 subunit designated-alpha2delta2-a and alpha2delta2-b
11/04/2004	CA2523459A1 Method of accumulating allergen-specific t cell antigen determinant in plant and plant having the antigen determinant accumulated therein
11/04/2004	CA2523452A1 Cancer specific monoclonal antibodies
11/04/2004	CA2523358A1 Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
11/04/2004	CA2523244A1 Tissue factor antibodies and uses thereof
11/04/2004	CA2523142A1 Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
11/04/2004	CA2522819A1 Polyvalent protein complex
11/04/2004	CA2522751A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
11/04/2004	CA2522718A1 A novel method of modulating bone-related activity
11/04/2004	CA2522400A1 Staphylococcus aureus efb protein and c3 binding region which inhibit complement activation
11/04/2004	CA2522081A1 Recombinant influenza viruses holding a mutation in a transmembrane protein gene
11/04/2004	CA2520097A1 Truncated baff receptors
11/04/2004	CA2519563A1 Cytokine-expressing cellular vaccine combinations
11/04/2004	CA2517134A1 Methods for obtaining colonization factors from bacterial strains
11/04/2004	CA2517010A1 Plasmid dna in combination with recombinant vsv for use in prime-boost immunization regimens
11/03/2004	EP1473369A2 Compositions and methods for delivery of genetic material
11/03/2004	EP1473367A1 Means and methods for diagnosing and treating affective disorders
11/03/2004	EP1473365A1 Angiogenesis inhibitors
11/03/2004	EP1473361A2 Genetically engineered attenuated viruses
11/03/2004	EP1473303A1 Novel proteins and dnas thereof
11/03/2004	EP1473041A2 Anti-allergic pharmaceutical composition
11/03/2004	EP1472544A2 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/03/2004	EP1472540A2 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
11/03/2004	EP1472515A2 MINRs AS MODIFIERS FO INSULIN RECEPTOR SIGNALING AND METHODS OF USE
11/03/2004	EP1472379A1 Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
11/03/2004	EP1472376A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo

1 ... 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 ... 1823